A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Bortezomib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Mesna; Pegfilgrastim
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 20 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Aug 2018.
- 18 Feb 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017, according to ClinicalTrials.gov record.
- 17 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.